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Abstract: Many systemic treatment options are available for advanced breast cancer, including 
endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) 
therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin 
(mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in 
Europe and the USA for patients suffering from estrogen receptor-positive, HER2-negative 
advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the 
results of BOLERO-2 (Breast cancer trials of OraL EveROlimus). This study showed a statisti-
cally significant and clinically meaningful improvement in median progression-free survival. 
Results concerning the impact on overall survival are expected in the near future. This clinically 
oriented review focuses on the use of mTOR inhibitors in breast cancer. Results reported with 
first-generation mTOR inhibitors (ridaforolimus, temsirolimus, everolimus) are discussed. The 
current and potential role of mTOR inhibitors is reported according to breast cancer subtype 
(estrogen receptor-positive HER2-negative, triple-negative, and HER2-positive ER-positive/
negative disease). Everolimus is currently being evaluated in the adjuvant setting in high-risk 
estrogen receptor-positive, HER2-negative early breast cancer. Continuing mTOR inhibition 
or alternatively administering other drugs targeting the phosphatidylinositol-3-kinase/protein 
kinase B-mTOR pathway after progression on treatments including an mTOR inhibitor is under 
evaluation. Potential biomarkers to select patients showing a more pronounced benefit are 
reviewed, but we are not currently using these biomarkers in routine practice. Subgroup analysis 
of BOLERO 2 has shown that the benefit is consistent in all subgroups and that it is impossible 
to select patients not benefiting from addition of everolimus to exemestane. Side effects and 
impact on quality of life are other important issues discussed in this review. Second-generation 
mTOR inhibitors and dual mTOR-phosphatidylinositol-3-kinase inhibitors are currently being 
evaluated in clinical trials.
Keywords: breast cancer, treatment, everolimus, mTOR inhibitors, biomarkers, phosphati-
dylinositol-3-kinase/protein kinase B-mTOR pathway
Introduction
Dysregulation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target 
of rapamycin (PI3K-AKT-mTOR) pathway is frequently observed in tumors, including 
breast cancer. This pathway plays an important role in the regulation of cell prolifera-
tion, metabolism, motility, angiogenesis, and survival. Pathway hyperactivation has 
been linked to cancer pathogenesis, progression, and treatment resistance.1 mTOR is a 
serine-threonine kinase which plays a key role in cell regulation, including responses 
to multiple stimuli such as amino acid availability, energy and oxygen stresses, and 
growth factor receptor signaling.2–5





Alterations in receptor tyrosine kinases can constitutively 
activate the PI3K-AKT pathway upstream in breast cancer, 
leading to increased activity of the mTOR pathway. Aberrant 
activation of insulin-like growth factor-1, the fibroblast 
growth factor receptor family, and the epidermal growth 
factor/HER family, in particular human epidermal growth 
factor receptor 2 (HER2) have all been observed in breast 
cancer.6 Abnormalities in the PI3K-AKT pathway itself 
including loss of phosphatase and tensin homolog (PTEN) 
function, PI3K mutations, and aberrant activation of AKT 
are other possibilities of mTOR pathway activation. The 
liver kinase B1 (LKB1)/adenosine monophosphate-activated 
protein kinase (AMPK) pathway is the other major pathway 
regulating mTOR. Hyperactivation of this pathway, known 
as the metabolic pathway, can also be responsible for mTOR 
pathway activation.
A close interaction between the mTOR pathway 
and estrogen receptor (ER) signaling has been reported. 
A  substrate of the mTOR complex 1, S6 kinase 1 phospho-
rylates the activation function domain 1 of the ER, leading 
to ligand-independent receptor activation.7,8
Many drugs in development target the PI3K-AKT-mTOR 
pathway, but only the mTOR inhibitor, everolimus, is cur-
rently approved for use in breast cancer in combination 
with the aromatase inhibitor exemestane in patients with 
ER-positive, HER2-negative advanced breast cancer who 
have previously failed a nonsteroidal aromatase inhibitor. 
This review focuses on first-generation mTOR inhibitors, 
their clinical results (Table 1), their common side effects 
(Table 2) including the impact on quality of life in Phase III 
trials, and perspectives of mTOR inhibitors in the treatment 
of advanced or early-stage breast cancer.
Clinical use of mTOR inhibitors
Dysregulation of the mTOR pathway leading to hyperacti-
vation of the pathway is associated with a poor outcome in 
breast cancer. Cancer cells develop resistance to endocrine, 
cytotoxic, and HER2-targeted therapy through activation 
of the PI3K-AKT-mTOR pathway. This is the rationale for 
addition of mTOR inhibitors to endocrine therapy, chemo-
therapy, and antiHER2 therapy with the aim of enhancing 
efficacy and/or delaying resistance.
Sirolimus was the first rapalog used as an immunosup-
pressant agent to prevent rejection in organ transplantation. 
Rapalogs also have proven clinical benefit in eluting stents 
to prevent coronary artery reocclusion. Three first-generation 
rapalogs, ie, temsirolimus, everolimus, and ridaforolimus, 
have been evaluated in inhibition of cancer growth. They differ 
from the structure of the parent drug, sirolimus, at position 
C-42 and have more favorable pharmacokinetics. They all bind 
to FK506-binding protein 12 (FKBP12) and all preferentially 
inhibit the functions of mTOR complex 1 (mTORC-1).9 These 
drugs seem to have similar clinical activity and toxic effects, 
but with some differences in metabolism, formulation, and 
schedule of administration. The class-specific side effects are 
well known, and include stomatitis, noninfectious pneumoni-
tis, infection, hyperglycemia, and dyslipidemia. Everolimus 
has been approved to overcome resistance to endocrine 
therapy, but there are a lot of clinical trials in progress com-
bining mTOR inhibitors with various endocrine, targeted, or 
cytotoxic drugs trying to overcome resistance to therapy.
Clinical studies evaluating  
mTOR inhibitors in breast cancer
Ridaforolimus
Ridaforolimus is an analog of sirolimus and has been admin-
istered orally in breast cancer trials at a dose of 40 mg/day for 
5 days per week. This drug is still investigational. In sarcoma, 
the drug offers moderate benefit as maintenance therapy after 
chemotherapy,10 but it has not yet been approved by the US 
Food and Drug Administration or European Medicines Agency 
in this indication. No randomized Phase II or III data are 
available in breast cancer. Two nonrandomized Phase II trials 
have finished recruitment, but the results are not yet available 
(oral deforolimus with trastuzumab for patients with HER2-
positive, trastuzumab-refractory metastatic breast cancer, 
NCT00736970; and a study of ridaforolimus in combination 
with dalotuzumab compared with standard of care treatment 
in ER-positive breast cancer patients, NCT01234857).11
Temsirolimus
Temsirolimus is currently approved for advanced renal cell 
carcinoma. The primary active metabolite of this prodrug 
is rapamycin. Temsirolimus is administered either orally or 
intravenously.
Temsirolimus weekly as a 30-minute intravenous infusion 
at a dose of 75 mg or 250 mg was evaluated in a random-
ized, open-label trial in 109 patients presenting with locally 
advanced or metastatic breast cancer.12 An objective response 
rate of 9.2% was reported in these heavily pretreated patients. 
The median time to progression was 12 weeks. Similar effi-
cacy was observed independent of the dose, but side effects 
were more frequent at the higher 250 mg dose.
A three-arm randomized Phase II trial evaluated the 
safety and activity of oral temsirolimus in combination with 
letrozole, a nonsteroidal aromatase inhibitor.13 The analysis 
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Table 1 Results of key clinical trials
Study Study design Patients Treatments Primary endpoint Secondary 
endpoints
ER-positive, HER2-negative advanced BC










Letrozole 2.5 mg daily,  
temsirolimus 30 mg daily,  
5 days every 2 weeks or  
letrozole 2.5 mg daily +  
placebo
Median PFS 
9 versus 8.9 months 
(comparable)
Median OS not 
reached (comparable) 
ORR 27% versus 27% 
SD at least 
24 weeks 
17% versus 19%









Tamoxifen 20 mg daily +  
everolimus 10 mg daily or  
tamoxifen 20 mg daily
6 month CBR 
61% versus 42% 
(exploratory analysis)
TTP 
8.6 versus 4.5 months 
Risk of death 
HR 0.45










exemestane 25 mg daily +  
everolimus 10 mg daily or 
exemestane 25 mg daily +  
placebo
Median PFS 





11 versus 4.1 months 
central review 
OS events 
25.4% versus 32.2% 
ORR 














vinorelbine 25 mg/m² weekly +  
trastuzumab 2 mg/kg/week +  
everolimus 5 mg daily or  
vinorelbine 25 mg/m² weekly +  
trastuzumab 2 mg/kg/week +  
placebo
Median PFS 
7 versus 5.78 months 
(difference statistically  
significant)
ORR 
40.8% versus 37.2% 
CBR 
59.2% versus 53.3% 
OS events 
36.3% versus 41.1%
ER-positive BC : neoadjuvant therapy






Letrozole 2.5 mg daily +  
everolimus 10 mg daily or 
letrozole 2.5 mg daily +  
placebo (4 months)
Clinical RR 68.1%  
versus 59.1% (difference 
statistically significant)
Antiproliferative 
response day 15 
(downregulation of 
Ki67 expression) 
57% versus 30% 
RR 58% versus 47% 
(ultrasound) 
RR 36.2% versus 
39.4% (mammography)
Abbreviations: eR, estrogen receptor; BC, breast cancer; RR, response rate; HeR2, human epidermal growth factor 2 receptor; Ai, aromatase inhibitor; PFS, progression-
free survival; OS, overall survival; CBR, clinical benefit rate; TTP, time to progression; HR, hazard ratio; NSAI, non-steroidal aromatase inhibitor; ORR, overall response 
rate; SD, stable disease.




mTOR inhibitors in breast cancer
was restricted to 92 patients included after amendment 
implementing a lower dose at treatment initiation (letrozole 
alone, 29 patients; letrozole + temsirolimus daily 10 mg, 33 
patients; letrozole + intermittent temsirolimus 30 mg daily 
during 5 days every 14 days, 30 patients) and suggested 
that both combined treatment arms had better median 
progression-free survival (not reached at time of reporting 
in the abstract) compared with the median progression-free 
survival of 9.2 months in the letrozole alone arm. Based 
on these encouraging results, a Phase III trial evaluating 
intermittent temsirolimus combined with letrozole has 
been initiated.
An ongoing Phase I–II trial is evaluating temsirolimus in 
combined treatment for metastatic HER2-positive or triple-
negative breast cancer (Temsirolimus plus neratinib for 
patients with metastatic HER2-amplified or triple-negative 
breast cancer, NCT01111825).11
Phase iii trial
A randomized placebo-controlled Phase III study (HORIZON) 
tested the efficacy and safety of first-line oral letrozole 2.5 mg 
daily + temsirolimus 30 mg intermittent daily (5 days every 
2 weeks) compared with letrozole + placebo in 1,112 patients 
with aromatase inhibitor-naive advanced breast cancer.14 
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Table 2 Side effects observed in key trials involving everolimus and temsirolimus
Neoadjuvant 
letrozole ±  
everolimus 
10 mg daily 
(Baselga et al15)
TAMRAD 
tamoxifen ±  
everolimus 
10 mg daily 
(Bachelot et al16)
BOLERO-2 
exemestane ±  
everolimus 




vinorelbine ±  





























































































































































































































































Abbreviations: eve, everolimus; NR, not reported.





The study was prematurely closed for futility at the  preplanned 
second interim analysis performed after 382 median 
progression-free survival events. The median progression-
free survival (9 and 8.9 months),  objective response rate 
(27% both arms), and clinical benefit rate (17% and 19%) 
were all similar in both arms of this trial. More grade 3 or 
4 toxicities were seen in the letrozole + temsirolimus arm 
(37% versus 24%). The median progression-free survival 
was also not increased by adding temsirolimus in the 40% 
of patients who had previously received endocrine therapy 




mTOR inhibitors in breast cancer
in the adjuvant setting. An exploratory analysis suggested 
improved median progression-free survival favoring 
letrozole + temsirolimus in postmenopausal patients aged 65 
years or younger. Persisting ovarian function in these younger 
patients and its detrimental effect in the letrozole alone arm 
have been given as a potential explanation for this finding by 
the authors. Unfortunately, blood samples are not available 
to prove this hypothesis. These disappointing results are in 
contrast with those of BOLERO-217 (Breast cancer trials of 
OraL EveROlimus, see below). The major difference between 
the two trials is that, in the temsirolimus trial, no patient had 
previously received an endocrine therapy for advanced breast 
cancer. Only 40% of the patients received previous endocrine 
therapy in the adjuvant setting. The authors can only assume 
as the data were not prospectively collected that the patients 
received tamoxifen, taking into account that the median dura-
tion of adjuvant endocrine therapy was 34 months, that the 
median time since last endocrine therapy was 5 months, and 
that no patient had received an adjuvant aromatase inhibitor 
within 12 months of study entry. The high number of HER2-
positive tumors (23% and an additional 36% of tumors with 
unknown status in the temsirolimus arm) has probably also 
contributed, because these patients need an anti-HER2 agent 
in the treatment regimen according to our current knowledge. 
Also, intermittent administration may not be the best schedule 
for optimal mTOR inhibition. Nevertheless, mTOR inhibitor-
related side effects such as stomatitis have been observed in 
many patients, suggesting that the target had been inhibited 
even with this intermittent schedule. Consequently, the differ-
ence in patient characteristics is probably the most important 
factor explaining these negative results.
everolimus
Proof-of-concept Phase ii trials  
in eR-positive, HeR2-negative breast cancer
Two proof-of-concept studies have shown that everolimus 
combined with an endocrine treatment is associated with a 
better outcome compared with the same endocrine thera-
pies used alone. Baselga et al evaluated the combination of 
letrozole 2.5 mg/day and everolimus 10 mg/day in the neo-
adjuvant setting in a randomized, placebo-controlled Phase 
II trial which enrolled 270 postmenopausal women.15 Neo-
adjuvant treatment was planned to be given over 4 months. 
The primary endpoint, response rate by clinical examination, 
was significantly improved from 59.1% to 68.1% in the com-
bined treatment arm. The patients had mandatory biopsies 
at baseline and at day 15, allowing key biomarker analyses 
as a secondary endpoint. Patients in both treatment arms 
showed a marked reduction in progesterone receptors and 
cyclin D1. A major reduction in phospo-S6 was only seen 
in the everolimus arm. Further, an antiproliferative response 
based on a reduction in Ki67 expression was more frequently 
seen in the everolimus arm than in the placebo arm (57% 
versus 30%, respectively). The relationship between specific 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit alpha (PI3KCA) mutations and Ki67 was also stud-
ied, but the small sample size has to be pointed out. With 
this important limitation in mind, it is interesting to note 
that exon 9 mutants, but not exon 20 mutants, had a rather 
poor antiproliferative response based on Ki67 proliferation 
marker expression in the placebo arm but a good response 
similar to all the other patients, including also patients 
with exon 20 mutations in the everolimus arm. TAMRAD 
(tamoxifen plus everolimus) is the other important proof-
of-concept study.16 This is a small, open-label, randomized 
Phase II study in the metastatic setting. One hundred and 
eleven postmenopausal patients have been randomized to 
receive either the antiestrogen agent tamoxifen 20 mg/day + 
everolimus 10 mg/day or tamoxifen alone. All patients had 
previously received an aromatase inhibitor either in the 
adjuvant or metastatic setting. Randomization was stratified 
according to primary or secondary resistance to aromatase 
inhibitor therapy. Primary resistance was defined as relapsing 
during or within 6 months of stopping adjuvant aromatase 
inhibitor treatment or progressing within 6 months of start-
ing aromatase inhibitor treatment in the metastatic setting. 
The primary endpoint was clinical benefit rate, ie, objective 
response or stable disease for at least 6 months according to 
RECIST17 (Response Evaluation Criteria In Solid Tumors) 
version 1.0. The clinical benefit rate was higher in the com-
bined treatment arm than in the tamoxifen alone arm (61% 
versus 42%). Concerning secondary endpoints, the median 
time to progression (4.5 months versus 8.6 months) and 
overall survival (hazards ratio [HR] 0.45) were also longer in 
the combined treatment arm. Interestingly, in an exploratory 
subgroup analysis, it has been shown that patients with sec-
ondary endocrine resistance had a more pronounced benefit 
than patients with primary resistance when everolimus was 
added to tamoxifen.
Phase iii trial: BOLeRO-2
Although these proof-of-concept trials are very important, 
the practice of oncology can only be changed based on 
randomized Phase III trials. Everolimus is now approved 
for the treatment of ER-positive, HER2-negative advanced 
breast cancer in combination with exemestane in patients 
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Table 3 Key messages concerning the BOLeRO-2 trial
Compared with exemestane alone, everolimus + exemestane improves 
median progression-free survival (3.2 months versus 7.8 months) in the 
treatment of estrogen receptor-positive, HeR2-negative advanced breast 
cancer resistant to nonsteroidal aromatase inhibitor therapy
The benefit is consistent among all prespecified clinical subgroups
Side effects are manageable. Patient education and appropriate dose 
modification according to existing guidelines are indicated
The most frequent clinically significant side effect is stomatitis. The most 
medically important side effect is noninfectious pneumonitis
Abbreviations: BOLeRO, Breast cancer trials of OraL eveROlimus; HeR2, human 
epidermal growth factor receptor 2.





resistant to nonsteroidal aromatase inhibitors by health 
authorities in Europe and the USA based on the BOLERO-2 
trial (Table 3).18,19
This was a randomized, placebo-controlled Phase III trial 
comparing exemestane 25 mg/day + everolimus 10 mg/day 
with exemestane and placebo in 724 patients previously 
treated with a nonsteroidal aromatase inhibitor in the adju-
vant or advanced setting. All patients suffered from recur-
rence of breast cancer during or within 12 months after the 
end of adjuvant treatment or progression during or within 1 
month after the end of treatment for advanced disease. It is 
important to point out that patients who fail treatment with a 
nonsteroidal aromatase inhibitor have a very poor prognosis 
with standard endocrine therapy alone. This has been shown 
in the EFECT (Evaluation of Faslodex versus Exemestane 
Clinical Trial) and SoFEA (Study Of Faslodex with or without 
concomitant arimidex vs Exemestane following progression 
on non-steroidal Aromatase inhibitors) trials.20,21 The median 
progression-free survival was less than 5 months with fulves-
trant (250 mg every 4 weeks) or exemestane in both trials. 
Combined endocrine therapy of anastrozole + fulvestrant 
(at the 250 mg dose) does not perform better compared with 
exemestane or fulvestrant monotherapy.21 These disappoint-
ing results illustrate well the unmet medical need in this 
patient population. The BOLERO-2 trial met its primary 
endpoint of median progression-free survival according to 
local assessment performed every 6 weeks. At the interim 
analysis, median progression-free survival was 6.9 months 
in the everolimus + exemestane arm compared with only 
2.8 months in the placebo + exemestane arm. These results 
were confirmed when the final progression-free survival 
results were presented (median progression-free survival 
7.8 and 3.2 months, respectively).19
Randomization was stratified according to the presence 
of visceral metastasis and previous sensitivity to endocrine 
therapy. Endocrine-sensitive patients were defined as having 
received at least 24 months of endocrine therapy before recur-
rence in the adjuvant setting or having presented a response 
or stabilization for at least 24 weeks of endocrine therapy for 
advanced disease. Visceral involvement was present in 56% of 
all patients and hormone-sensitive disease in 84%. Importantly, 
the improvement in median progression-free survival was 
consistent among all predefined subgroups including (but not 
limited to) age, race, baseline performance status, progesterone 
receptor status, prior chemotherapy for advanced disease, 
prior endocrine therapy other than a nonsteroidal aromatase 
inhibitor, presence of visceral disease, bone only disease, and 
sensitivity to prior endocrine therapy.19
Of course, the absolute benefit was less pronounced in 
poor prognostic subgroups but the relative benefit was very 
similar in all subgroups. For example, median progression-
free survival according to local assessment increases from 
2.76 months to 6.83 months in patients with visceral disease, 
from 4.21 months to 9.86 months in patients without visceral 
disease, and from 5.29 months to 12.88 months in patients 
with bone only disease. Very interestingly, the median progres-
sion-free survival increases from 4.17 months to 11.7 months 
in patients having received nonsteroidal aromatase inhibitor 
therapy in the adjuvant setting but having not yet received 
any treatment for advanced disease. This important absolute 
benefit is observed in patients who just failed one line of 
endocrine therapy. Patients do not need to be heavily pretreated 
before benefiting from the combined treatment approach. 
BOLERO-2 has shown that everolimus + exemestane offers 
an important alternative to chemotherapy for the large subset 
of patients who do not have life-threatening visceral metastatic 
disease.22 The use of chemotherapy can be postponed in most 
patients with visceral metastases.
Concerning the secondary endpoint, analysis of pro-
gression-free survival based on central radiologic assess-
ment, a 6.9-month prolongation in median progression-free 
survival from 4.1 months in the placebo + exemestane arm 
to 11 months in the everolimus + exemestane arm was 
observed.19 We are eagerly awaiting the results for overall sur-
vival. Mature data are expected to be presented in 2014. The 
absolute difference in deaths was increasing progressively 
since the first interim analysis of median progression-free 
survival, and was 6.8% (25.4% versus 32.2%) at last update 
at time of final progression-free survival analysis, indicating 
a better outcome in the everolimus + exemestane arm, but 
this difference is not yet statistically significant.19
Future clinical trials in the adjuvant setting
Two investigator-initiated studies will evaluate the role of 
everolimus in the adjuvant setting (Safety study of adding 
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everolimus to adjuvant hormone therapy in women with 
poor prognosis, ER-positive and HER2-negative primary 
breast cancer, free of disease after receiving 3 years 
of adjuvant hormone therapy, NCT01805271; S1207 
hormone therapy with or without everolimus in treating 
patients with breast cancer, NCT01674140).11 In Europe, 
the UNICANCER group in France has started a large 
placebo-controlled Phase III trial expected to recruit 2,010 
premenopausal or postmenopausal women suffering from 
ER-positive, HER2-negative breast cancer presenting at 
least four lymph nodes involved at diagnosis. Patients 
initially receive routine standard adjuvant therapy for 2–3 
years. Only patients still relapse-free after 2–3 years of 
adjuvant therapy can enter the trial. Patients then receive 
everolimus or placebo for 2 years in addition to tamoxifen 
or aromatase inhibitor therapy. The primary endpoint is 
disease-free survival at 2 years post- randomization, and 
secondary endpoints include overall survival, biomarker 
assessments, and safety. The investigators have chosen 
this design with everolimus treatment starting only after 
some years of endocrine therapy because their previous 
TAMRAD study has shown in an exploratory analysis that 
patients with secondary endocrine resistance had a much 
more pronounced benefit compared with patients with 
primary resistance when everolimus is added to tamoxifen 
(see above).16
The other large placebo-controlled Phase III trial is 
organized by the Southwest Oncology Group and National 
Surgical Adjuvant Breast and Bowel Project.11 In this 
trial, everolimus or placebo is given in combination with 
standard endocrine therapy as soon as the patient starts 
endocrine therapy for a total duration of 1 year. A total of 
3,500 high-risk patients are expected to be recruited into this 
trial. High risk is defined as an Oncotype DX® recurrence 
score over 25 or at least four lymph nodes involved.23 Use 
of chemotherapy in the adjuvant or neoadjuvant setting is 
mandatory in this study in contrast with the  European study. 
The primary endpoint is invasive disease-free  survival. 
Secondary endpoints include overall survival, distant 
recurrence-free survival, biomarker assessments, and safety. 
Compliance with the experimental treatment arm in both 
studies may be an issue because combined treatment with 
everolimus is more toxic than endocrine therapy alone. 
Everolimus has never been evaluated in the adjuvant setting 
in any tumor type. Consequently, no data concerning the 
acceptance rate in the adjuvant setting are available. In the 
neoadjuvant setting, twice as many patients discontinued 
everolimus + letrozole compared with placebo + letrozole 
(18.8% versus 9.1%).15 If a significant number of patients, 
for personal reasons, stop all adjuvant treatment including 
standard endocrine therapy in the case of poor tolerance of 
everolimus this may have a significant impact on the results 
in the experimental arm, in particular in the trial performed 
in the USA where everolimus or placebo is given as soon 
as endocrine therapy starts.
What is the efficacy of everolimus in the first-line 
setting in patients who have never been exposed 
to endocrine therapy? Should we change endocrine 
therapy and continue the mTOR inhibitor at time  
of progression?
BOLERO-4 (Open-label, Phase II, study of everolimus 
plus letrozole in postmenopausal women with ER-positive, 
HER2-negative  metastatic or locally advanced breast cancer, 
NCT01698918)11 is a nonrandomized trial evaluating the 
first-line effectiveness of everolimus 10 mg/day in combina-
tion with letrozole 2.5 mg/day in endocrine therapy-naïve 
patients presenting advanced breast cancer. The first-line use 
of everolimus in endocrine-naïve patients is still the subject 
of major debate after the negative first-line temsirolimus 
trial.14 At the time of disease progression, patients have the 
option to continue everolimus at the same dose combined 
with exemestane 25 mg/day instead of letrozole. Given 
that this is a nonrandomized trial, the results can only be 
hypothesis-generating, but the usefulness of continuing 
mTOR inhibition after progression during mTOR therapy 
in particular is a very relevant clinical question. In HER2-
positive disease, we give several lines of trastuzumab-based 
treatment. It is worthwhile to evaluate if this kind of approach 
is also of interest for agents blocking the PI3K-AKT-mTOR 
pathway. This concept has also been validated in colorectal 
cancer, where antiangiogenic drugs are continued beyond 
progression although a different antiangiogenic drug is 
used after progression. The administration of subsequent 
lines of endocrine therapy in metastatic ER-positive breast 
cancer is also standard of care. Another important question 
is whether, in the event of progressive disease, the optimal 
treatment should be continuation of the same mTOR inhibitor 
or if another drug targeting the PI3K-AKT-mTOR pathway 
should be administered in addition to a modified endocrine 
therapy. The latter strategy is being evaluated for example 
in the BELLE-3 trial (A Phase III study of BKM120 with 
fulvestrant in patients with hormone receptor-positive, 
HER2-negative, aromatase inhibitor treated locally advanced 
or metastatic breast cancer who progressed on or after mTOR 
inhibitor, NCT01633060)11 where patients who have failed 
Breast Cancer: Targets and Therapy 2014:6
Table 4 Key messages concerning the BOLeRO-3 trial
The trial met its primary endpoint: median progression-free survival is 
increased when everolimus is added to trastuzumab and vinorelbine 
compared with placebo, trastuzumab, and vinorelbine
The average benefit in median progression-free survival is only 5 weeks, 
indicating the need to identify patients who benefit most
The benefit is more pronounced in estrogen receptor-negative tumors 
(hazards ratio 0.65)
New treatment approaches are needed for HeR2-positive, estrogen 
receptor-positive tumors. in particular, a treatment strategy including an 
endocrine agent should also be evaluated
Abbreviations: BOLeRO, Breast cancer trials of OraL eveROlimus; HeR2, human 
epidermal growth factor receptor 2.





everolimus + exemestane are randomized to receive fulves-
trant ± BKM120, a PI3K inhibitor.
Another question is whether administration of everolimus 
should be considered again in a later line of therapy after 
use of other drugs targeting the PI3K-AKT-mTOR pathway 
rather than at the time of progressive disease during treat-
ment with everolimus.
is everolimus + exemestane at least as effective  
as capecitabine after failure of a nonsteroidal 
aromatase inhibitor? is everolimus alone as  
effective as combined therapy with exemestane?
Another Phase II open-label but randomized trial is 
BOLERO-6 (A Phase II study of everolimus in combi-
nation with exemestane versus everolimus alone versus 
capecitabine in advanced breast cancer, NCT01783444).11 
A total of 300 postmenopausal patients with progressive 
disease during or soon after nonsteroidal aromatase inhibi-
tor therapy will receive either everolimus + exemestane, 
everolimus alone, or capecitabine. The primary endpoint 
is progression-free  survival for the comparison of everoli-
mus + exemestane versus exemestane monotherapy based 
on local radiologic assessment performed every 6 weeks. 
Comparison of everolimus + exemestane versus capecit-
abine is the key secondary endpoint. Overall survival, 
objective response rate, clinical benefit rate, safety, quality 
of life, patient treatment satisfaction, and potential biomark-
ers that may predict sensitivity to everolimus will also be 
 evaluated. Although everolimus has some single-agent 
activity, our current understanding is that we should target 
both the estrogen signaling pathway and the PI3K-AKT-
mTOR pathway. This trial will give additional information 
concerning the single-agent activity of everolimus. It is 
reasonable to expect that the combined approach is more 
effective and, as exemestane is in general well tolerated in 
patients who have already received a nonsteroidal aromatase 
inhibitor, we do not expect that everolimus monotherapy 
will be used in breast cancer in the future, although this is 
the case for example in renal cell carcinoma. The compari-
son of everolimus + exemestane with capecitabine is much 
more interesting from a clinical point of view, although of 
course this is just a secondary endpoint in a Phase II trial. 
Nevertheless, it will be very interesting to see a head-to-
head comparison between a standard oral chemotherapy 
and a combined treatment approach between an endocrine 
agent and everolimus, particularly in patients suffering from 
visceral metastases. Randomization is stratified according 
to visceral involvement in this trial.
BOLeRO-3: Phase iii trial in HeR2-positive disease
Nonrandomized Phase I/II trials have shown everolimus to 
have promising activity when combined with other agents, ie, 
either trastuzumab alone or combined with trastuzumab and 
chemotherapy (paclitaxel or vinorelbine) in HER2-positive 
disease.24–27
O’Regan et al presented the final progression-free survival 
analysis of the BOLERO-3 study28 at the 2013 American 
Society of Clinical Oncology meeting. This randomized, 
double-blind, placebo-controlled, multicenter Phase III trial 
compared weekly trastuzumab + vinorelbine and everolimus 
at the dose of 5 mg with weekly trastuzumab + vinorelbine 
and placebo. A total of 569 patients with advanced breast 
cancer who had previously failed trastuzumab and a taxane 
were recruited into this trial.  Progressive disease was either 
observed during treatment with trastuzumab in the adjuvant 
or metastatic setting or during the 12 months following 
completion of trastuzumab therapy in the adjuvant setting 
(Table 4). The trial met its primary endpoint progression-
free survival. Indeed, the median progression-free survival 
increases from 5.78 months to 7 months in the experimental 
arm. More stomatitis and neutropenic fever were observed 
in the experimental arm. Stomatitis was also the reason 
why in the Phase I/II trial the everolimus dose had not 
been increased to the standard 10 mg dose which allows 
optimal inhibition of the mTOR pathway.27 Subgroup 
analysis revealed a more pronounced benefit in patients 
who previously received trastuzumab in the adjuvant or 
neoadjuvant setting (HR 0.65), in those without visceral 
involvement (HR 0.48), and in those with ER-negative 
disease (HR 0.65). Neither the objective response rate nor 
the clinical benefit rate have been improved by addition of 
everolimus. However, very interestingly, only 36.3% in the 
everolimus arm compared with 41.1% in the placebo arm 
had died at the time of the interim overall survival analysis. 
We are now waiting for the mature overall survival data in 
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Phase ib/ii trials of RAD001 in triple-negative  
metastatic breast cancer
NCT01939418
A study of lapatinib in combination with everolimus in  
patients with advanced, triple-negative breast cancer
NCT01272141
NeCTAR: everolimus plus cisplatin in triple-negative  
breast cancer
NCT01931163
Temsirolimus plus neratinib for patients with metastatic 
HER2-amplified or triple-negative breast cancer
NCT01111825
Study of temsirolimus, erlotinib, and cisplatin in  
solid tumors
NCT00998036
Cisplatin and paclitaxel with or without everolimus in  
treating patients with stage ii or stage iii breast cancer
NCT00930930
RAD001 plus carboplatin in breast cancer patients NCT01127763
Cisplatin, paclitaxel, and everolimus in treating  
patients with metastatic breast cancer
NCT01031446
Trial of RAD001 in triple-negative metastatic  
breast cancer
NCT00827567
Phase i/ii study of weekly nab-paclitaxel and RAD001  
in women with locally advanced or metastatic  
breast cancer
NCT00934895
Study to compare vinorelbine in combination with  
the mTOR inhibitor everolimus versus vinorelbine  
monotherapy for second-line treatment in  
advanced breast cancer
NCT01520103
Trial of paclitaxel/bevacizumab ± everolimus for  
patients with HeR2-negative metastatic breast cancer
NCT00915603
Efficacy of RAD001 in breast cancer patients with  
bone metastases
NCT00466102
Paclitaxel followed by FeC versus paclitaxel and  
RAD001 followed by FeC in women with breast cancer
NCT00499603
Abbreviations: FEC, fluorouracil, epirubicin, and cyclophosphamide; HER2, human 
epidermal growth factor receptor 2.
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order to determine if this trend will result in a statistically 
significant survival benefit.
expected additional study results in the near future
In 2014 we expect the results of the BOLERO-1 study 
(Everolimus in combination with trastuzumab and paclitaxel 
in the treatment of HER2-positive locally advanced or 
metastatic breast cancer, NCT00876395)11 evaluating everoli-
mus in less heavily pretreated HER2-positive breast cancer 
patients. This trial is comparing everolimus at a dose of 10 
mg daily combined with weekly trastuzumab and paclitaxel 
with placebo and weekly trastuzumab and paclitaxel in the 
first-line advanced disease setting.
Triple-negative disease
Triple-negative breast cancers are very heterogeneous and 
represent a very aggressive subtype of breast cancer that 
lacks expression of ER and HER2. It is a real challenge to 
find specific systemic therapies according to targets present in 
the tumor with the aim of improving the prognosis of triple-
negative breast cancer. Immunohistochemistry analyses have 
shown that activated mTOR is more frequently observed in 
triple-negative breast cancer (36%) than in other subtypes 
of breast cancer and is associated with poor outcome.29,30 
Loss of PTEN or PI3KCA mutations have also been reported 
in triple-negative breast cancer, but less frequently compared 
with other breast cancer subtypes.31 Many clinical trials have 
evaluated mTOR inhibitors in triple-negative breast cancer 
(Table 5), but few results have been reported.11 Preliminary 
results of a study in the neoadjuvant setting were presented 
at the 2013 San Antonio Breast Cancer Symposium.32 The 
pathologic complete response rate was not improved by 
adding everolimus to the standard neoadjuvant regimen in 
the control arm.
Nonresponsive HeR2-negative tumors  
treated by neoadjuvant chemotherapy
Huober et al33 reported a study evaluating the role of everoli-
mus in addition to paclitaxel as a drug resistance-modulating 
agent in patients with HER2-negative tumors not responding 
to initial neoadjuvant cytotoxic therapy (epirubicin + cyclo-
phosphamide) combined with or without antiangiogenic 
(bevacizumab) therapy. Patients without a clinical response 
were randomized to receive weekly paclitaxel (80 mg/m²) 
with or without everolimus (5 mg daily after a stepwise dose 
escalation starting from 2.5 mg every other day; daily full 
dose starting day 13) for 12 weeks. A total of 403 patients 
were randomized. The number of patients randomized in this 
substudy was lower than expected, and consequently, this 
substudy is unfortunately underpowered. The hypothesis was 
that adding everolimus to paclitaxel improves the pathologic 
complete response, defined as no invasive and no noninvasive 
residuals in breast and nodes from 5% to 12.1%; 566 patients 
had to be recruited to confirm this hypothesis. A total of 18 
(4.6%) patients, ie, seven (3.6%) treated with paclitaxel and 
everolimus and eleven (5.6%) treated with paclitaxel alone 
had a pathologic complete response. This trial indicates 
that neoadjuvant therapy with everolimus and paclitaxel 
for patients with HER2-negative disease unresponsive to 
epirubicin-based and cyclophosphamide-based chemo-
therapy, with or without bevacizumab, did not improve the 
pathologic complete response rate. However, longer follow-
up is needed to test the impact on other endpoints, such as 
progression-free survival and overall survival. Impact on the 
pathologic complete response rate is not necessarily the best 
endpoint for evaluating the potential role of everolimus in 





this specific patient population. Breast-conserving treatment 
was performed in 54.4% of patients with the combination 
treatment and in 61.9% of those receiving paclitaxel alone 
(difference not statistically different). As expected, side 
effects (including mucosal inflammation, thrombocytope-
nia, neutropenia, infection, diarrhea, allergic reactions, and 
skin rash) were more frequent when everolimus was added. 
Chemotherapy was discontinued in 11.6% of patients treated 
with paclitaxel alone and in 21.8% of patients treated with 
paclitaxel and everolimus.
Side effects of mTOR inhibitors  
in key Phase III studies and  
impact on quality of life
Temsirolimus
In the HORIZON trial (letrozole + intermittent temsirolimus 
versus letrozole + placebo), treatment-emergent adverse 
events were more frequently seen in the temsirolimus arm 
(91% versus 79%).14 All grade side effects included asthenia 
(27% versus 21%), mucositis/stomatitis (26% versus 4%), 
diarrhea (21% versus 9%), headache (19% versus 12%), 
anorexia (15% versus 7%), and rash (15% versus 4%). Grade 
3 or 4 toxicities were also more frequent in the temsirolimus 
arm (37% versus 24%), and included hyperglycemia (4% ver-
sus 1%), diarrhea (2% versus 1%), mucositis/stomatitis (2% 
versus 1%), and hyperlipidemia (2% versus 1%).  Permanent 
dose reduction (4% versus 1%) and therapy discontinua-
tion were also more frequent in the experimental arm. No 
increase in noninfectious pneumonitis was reported in the 
experimental arm. The authors suggested that the overall 
much lower frequency of toxicities in HORIZON compared 
with BOLERO-2 can be related to a less heavily pretreated 
patient population. However, less effective inhibition of the 
mTOR pathway, in particular with intermittent administra-
tion, should be considered as an alternative explanation. The 
mean relative dose intensity of temsirolimus was very high 
(0.96). The impact of side effects on quality of life was not 
reported in this trial.
everolimus
In the BOLERO-2 (exemestane + everolimus versus exemes-
tane + placebo), serious adverse events related to study treat-
ment were much more frequent in the everolimus arm (12% 
versus 1%).17 Also, a higher percentage of patients discontinued 
everolimus compared with placebo in the control group because 
of adverse events (19% versus 4%) or withdrawal of consent 
(5% versus 2%). Seven deaths were attributed to treatment in the 
everolimus arm. The most common grade 3 or 4 adverse events 
were stomatitis (8% versus 1%), anemia (6% versus ,1%), 
dyspnea (4% versus 1%), hyperglycemia (4% versus ,1%), 
fatigue (4% versus 1%), and pneumonitis (3% versus 0%). All 
grade adverse events independent of relationship to study treat-
ment were also in general more frequent in the everolimus arm, 
ie, stomatitis (56% versus 11%), rash (36% versus 6%), fatigue 
(36% versus 29%), diarrhea (30% versus 16%), decreased 
appetite (29% versus 10%), cough (22% versus 11%), and 
dyspnea (18% versus 9%).
Quality of life was an important secondary endpoint in 
BOLERO-2 and was assessed by the European Organisa-
tion for Research and Treatment of Cancer Quality of Life 
Questionnaire-Core 30 (EORTC QLQ-C30) done at baseline 
and thereafter every 6 weeks until disease progression and/or 
discontinuation of treatment.34 Time to definitive deterioration 
analysis at a 5% decrease in the quality of life score versus 
baseline, with no subsequent increase above this threshold, 
was evaluated prospectively. The median time to definitive 
deterioration in quality of life was 8.3 months in the combined 
treatment arm versus 5.8 months in the control arm (HR 0.74; 
P=0.0084). The authors reported an additional sensitivity anal-
ysis using a 10-point minimal important difference decrease in 
the global health status score versus baseline. The median time 
to definitive deterioration in the combined treatment arm was 
11.7 months versus 8.4 months in the control arm (HR 0.80; 
P=0.1017). These results show that quality of life was at least 
maintained in the experimental arm and that side effects were 
largely compensated by a better antitumoral effect in patients 
receiving everolimus in addition to exemestane.
In the BOLERO-3 trial (trastuzumab + vinorelbine + 
everolimus versus trastuzumab + vinorelbine + placebo), 
more patients discontinued treatment because of adverse 
events (10% versus 5%) and because of withdrawal of consent 
(6% versus 5%) in the everolimus arm.28 The median relative 
dose intensity was 0.77 for everolimus and 0.96 for placebo. 
The median relative dose intensity for vinorelbine was lower 
in the experimental arm (0.64 versus 0.73). More frequent 
all grade adverse events in the everolimus arm included 
stomatitis (63% versus 28%), pyrexia (39% versus 23%), 
decreased appetite (33% versus 17%), and febrile neutrope-
nia (17% versus 4%). Several grade 3 toxicities were also 
more frequent in the everolimus arm, and included stomatitis 
(13% versus 1%), fatigue (12% versus 4%), diarrhea (4% 
versus 1%), hyperglycemia (grade 3, 4% versus 2%; grade 
4, 2% versus 1%), and nausea (3% versus 1%), but not non-
infectious pneumonitis (,1% versus 1%). The incremental 
toxicity observed in the everolimus arm compared with 
the placebo arm did not impact quality of life. The time to 
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definitive deterioration of global health status score based on 
the EORTC QLQ-C30 questionnaire and defined as at least a 
10% change from baseline was 8.31 months in the everolimus 
arm and 7.29 months in the placebo arm.
Management of side effects
Dose interruption and/or modification are key elements for 
the management of side effects. In general, the dose interrup-
tion and/or modification guidelines used in the key clinical 
trials discussed above should be used in routine care. Patient 
education is also very important in our opinion. When we start 
everolimus in our center, we inform our patients concerning 
early symptoms and optimal management, in particular for 
stomatitis and noninfectious pneumonitis. The patients are 
also invited to contact us as soon as any significant problem 
appears. We have the advantage that most of our patients are 
living close to our hospital (most often within 30 km). Con-
cerning stomatitis, all our patients receive a prescription for 
a corticosteroid and analgesic-containing mouth bath to be 
started as soon as even mild stomatitis appears. As discussed 
above, some trials are evaluating even prophylactic mouth 
baths and some colleagues have reported very good results 
with this approach (unpublished data), but we do not use 
mouth baths prophylactically in our center. Others recom-
mend a rapid progressive increase in the everolimus dose 
before reaching the recommended 10 mg daily.  However, 
neither the efficacy nor the impact on the incidence of 
stomatitis has been evaluated prospectively within a clinical 
trial and consequently we do not recommend this approach. 
In patients with more severe pain we consider daily local 
laser therapy because we have observed major benefit on 
pain, rapidly after therapy. We use this approach routinely, 
although we have to admit that this approach has also not 
been prospectively evaluated within a clinical trial. In the 
event of grade 2 stomatitis (symptomatic patient, but can 
eat and follow a modified diet) we do a transient dose inter-
ruption. After recovery to grade 1, we restart at the 10 mg 
dose. It is not unusual to see that the patients are now able to 
tolerate the 10 mg dose, although some will present a relapse 
of grade 2 stomatitis, and after a second dose interruption 
we restart everolimus in these patients at a reduced dose of 
5 mg. Patients are educated in our center about good oral 
hygiene. We suggest that they avoid spicy food. We ask that 
they come back immediately to the clinic if they develop more 
extensive stomatitis (more than three lesions), if the lesions 
are lasting over 3 days, and if they interfere with eating and 
drinking. In our experience, grade 3 stomatitis (a symptom-
atic patient who is unable to adequately aliment or hydrate 
orally) can be avoided by patient education. We also explain 
to our patients that, based on the experience in BOLERO-2, 
stomatitis generally starts within the first month, and ask 
them to come back for a routine visit in the office at day 15, 
and during this visit we check in particular if the patient has 
any sign of early onset of stomatitis.
All our patients are aware that cough and dyspnea can be the 
first symptoms related to noninfectious pneumonitis. They are 
asked to come back immediately to our office if they develop 
any significant cough and/or dyspnea in order to perform further 
work-up. They are also informed that, based on the BOLERO-2 
trial experience, noninfectious pneumonitis can occur at any 
time point during treatment with everolimus. We perform a 
chest computed tomography (CT) scan routinely before start-
ing everolimus in all patients in order to have a baseline CT 
that can be used for comparison if the patient presents later 
with any abnormality on chest CT. As recommended in the 
guidelines, we do not interrupt treatment or adapt the dose in 
patients with grade 1 noninfectious pneumonitis (asymptomatic 
patient, radiographic finding only), but immediately interrupt 
everolimus in a symptomatic patient suffering from noninfec-
tious pneumonitis. After recovery to grade 1 noninfectious 
pneumonitis, we try to restart at a reduced dose of 5 mg. In 
symptomatic patients, we consider high-dose corticosteroid 
therapy (at least 1 mg/kg/day methylprednisolone) because 
this approach generally allows very rapid improvement of the 
symptoms. We recommend continuing high-dose corticoster-
oids for at least 4 weeks because we have seen rapid recurrence 
of severe noninfectious pneumonitis in a patient after a short 
course of corticosteroid therapy.
We have no specific recommendations for the manage-
ment of the other common everolimus-related side effects, 
and simply follow the available guidelines at our center.
what is the optimal dose: 5 mg or 10 mg daily?
Ravaud et al35 performed a meta-analysis of clinical trials 
in oncology in order to evaluate the potential relationship 
between everolimus exposure and safety and efficacy. 
 Previous studies have shown that maximum everolimus 
concentrations are reached 1–2 hours after administering 
5–70 mg oral doses,36 maximum everolimus concentrations 
increase in a dose-proportional manner between 5 mg and 
10 mg,36 continuous 5–10 mg once-daily dosing enables 
steady state to be achieved within 1 week,36 and the minimum 
concentration demonstrates a linear dose-through relation-
ship.37 Individual patient data from five Phase II or Phase 
III studies, in which steady-state, predose pharmacokinetic 
samples were taken from patients with solid tumors receiving 





10 mg daily, were pooled in the meta-analysis.35 No patients 
with breast cancer were included. Efficacy and safety were 
evaluable for 945 and 938 patients, respectively. A two-
fold increase in the minimum concentration of everolimus 
increased the probability of tumor size reduction (odds 
ratio 1.4), was associated with a trend for reduced risk of 
progression-free survival events (risk ratio [RR] 0.9), and 
increased the risk of at least grade 3 pulmonary toxicity (RR 
1.93), stomatitis (RR 1.49), and metabolic toxicity (RR 1.3). 
A very important remaining question is whether experienc-
ing an adverse event is associated with improved efficacy. 
The data reported in the meta-analysis suggest that this is 
indeed the case, because increased exposure to everolimus is 
associated with both increased efficacy and a higher rate of 
high-grade toxicities. Future studies should consider assess-
ing the everolimus concentration at the time of occurrence 
of adverse events.
This meta-analysis, although not in the field of breast 
cancer, clearly suggests a dose-dependent antitumor effect 
of everolimus. Some clinicians suggest starting at 5 mg 
instead of the recommended 10 mg daily dose. The data 
available are definitely against this approach. The optimal 
dose can only be further explored within a randomized pro-
spective clinical trial. For the routine care of our patients, 
we have to respect the approved dose and regimens. Dose 
reductions should only be performed according to man-
agement guidelines in patients presenting some specific 
high-grade toxicities. All patients should receive everoli-
mus 10 mg in combination with exemestane based on the 
BOLERO-2 trial.
Biomarker data in key  
Phase II and III studies
everolimus
TAMRAD
Sixty-six formalin-fixed paraffin-embedded primary breast 
tumors were retrospectively collected in the TAMRAD 
study.38 Data for 55 patients (50% of the intention-to-treat 
patient population) were finally available, and biomarkers in 
the canonical and metabolic pathways as well as downstream 
effectors evaluating pathway activation were presented at 
the 2013 American Society of Clinical Oncology meeting. 
The results suggest that high phosphorylated 4E-binding 
protein 1 (p4EBP-1), low liver kinase B1 (LKB1), and low 
PI3K are associated with higher efficacy of mTOR inhi-
bition in these tumors. A prospective validation of these 
hypothesis-generating results is needed in an independent 
patient cohort.
BOLeRO-2
At the same American Society of Clinical Oncology meeting, 
Hortobagyi et al39 reported biomarker data from BOLERO-2.40 
A large panel of oncogenes and tumor suppressor genes were 
sequenced using next-generation sequencing of 309 formalin-
fixed paraffin-embedded archival tissue samples. Successful 
analysis was obtained in 227 samples, representing 32% of 
the intention-to-treat patient population. No major baseline 
clinical or demographic differences were observed between 
the intention-to-treat and the next-generation sequencing 
populations. Clinical efficacy was also comparable between 
these populations. There were 1,476 sequence alterations, 
including 1,222 missense mutations. There were 548 copy num-
ber alterations, including 522 amplifications (at least six cop-
ies). Genetic alterations were most frequently seen in PI3KCA 
(47.6%, mostly missense mutations), cyclin D1 (CCND1) 
(31.3%, gene amplifications), TP53 (23.3%, missense and 
other sequence alterations), and FGFR1 (18.1%, mostly gene 
amplifications). Many other less frequent genetic alterations 
were also reported in other genes, some in the same pathways as 
the pathways which contain the most frequently altered genes. 
This retrospective exploratory analysis was unable to define any 
predictive biomarker identifying subgroups of patients, defined 
by each of the four most frequently altered genes/pathways 
assessed individually, who do not benefit from the addition 
of everolimus. A greater benefit from everolimus treatment 
was derived in patients (representing 76% of the biomarker 
population) with minimal genetic alterations in PI3KCA/
PTEN/CCND1 or FGFR1/2 genes in a combined analysis (HR 
0.24 for wild-type patients and 0.26 for patients with a single 
gene alteration favoring everolimus-based therapy). Patients 
with tumors having multiple gene alterations experienced less 
benefit, but still did better than those on exemestane alone (HR 
0.78). It is not fully understood why patients with multiple gene 
abnormalities in these particular pathways benefit less than 
patients with no, or a single alteration.
BOLeRO-3
Preliminary biomarker data from BOLERO-3 were presented 
at the European Cancer Congress meeting in Amsterdam in 
2013.41 Archival tumor samples were available for biomarker 
analysis from 283 of 569 patients. Candidate biomarkers 
 reflecting activation of the PI3K-mTOR pathway evaluated 
in this exploratory analysis were high phosphorylated S6 
(pS6), low PTEN, and PI3KCA mutations. Results for at least 
one of these candidate biomarkers were available for 46% 
of the intention-to-treat patient population, and suggest that 
addition of everolimus may be most beneficial for patients 
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with low PTEN or high pS6 levels. Addition of everolimus in 
these patient subgroups was respectively associated with an 
absolute benefit of 4 and 3 months in median progression-free 
survival compared with patients receiving only trastuzumab, 
 vinorelbine, and placebo. No correlation with PI3KCA 
mutational status has been observed, but sample size may 
be a critical issue. These observations need of course to be 
confirmed in an independent cohort.
Future directions
Second-generation mTOR inhibitors  
and dual mTOR-Pi3K inhibitors
The objective response rates achieved with everolimus and 
other first-generation mTOR inhibitors are modest.42 mTOR 
forms at least two functional multiprotein complexes, ie, 
mTORC1 and mTORC2.43 First-generation mTOR inhibi-
tors inhibit mTORC1 but not mTORC2, which also plays 
an important role in cancer growth and survival (Figure 1). 
 Furthermore, treatment with first-generation mTOR inhibitors 
may also cause activation of AKT via a negative  feedback loop, 
resulting in increased cancer cell survival.44,45 Consequently, 
PI3K/mTOR or mTORC1/2 dual inhibitors are currently under 
evaluation because these drugs can prevent elevated AKT activ-
ity and provide more complete inhibition of mTOR activity.
Immunosuppression is a concern for mTOR kinase inhibi-
tors because more potent suppression of mTOR signaling will 
potentially lead to impaired immune surveillance and poten-
tially an increased risk of new cancer and metastatic progres-
sion. Increased toxicity can also become a problem with more 
potent pan-kinase blockade. Ongoing studies will evaluate if 
inhibiting multiple points of the PI3K-AKT-mTOR signaling 
cascade is more effective than blockade at a single node, and 
if catalytic mTOR kinase inhibitors can really achieve a more 
favorable balance of efficacy and tolerability.
Conclusion and perspectives
We are living in an exciting time for breast cancer special-















Figure 1 Mechanism of action of different classes of mTOR inhibitors (rapalogs) already approved or under development.
Abbreviations: iRS-1, insulin receptor substrate 1; Pi3K, phosphatidylinositol-3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; PTeN, phosphatase 
and tensin homologue; S6K1, S6 kinase 1; 4e-BP1, eiF4e-binding protein 1.
Table 6 Key questions in ongoing clinical trials
will the BOLeRO-2 trial show an overall survival benefit favoring 
patients receiving everolimus combined with exemestane?
Is there a role for everolimus in the first-line treatment of estrogen 
receptor-positive HeR2-negative advanced breast cancer not previously 
exposed to any endocrine therapy?
Should everolimus or a drug targeting the Pi3K-AKT-mTOR pathway be 
part of the next or later line of treatment for tumors progressing while 
receiving a regimen containing an mTOR inhibitor?
is there any role for everolimus in the adjuvant treatment of high-risk, 
early-stage estrogen receptor-positive, HeR2-negative breast cancer?
Is there any overall survival benefit in the BOLeRO-3 trial comparing 
trastuzumab, vinorelbine, and everolimus with trastuzumab, vinorelbine, 
and placebo in heavily pretreated HeR2-positive advanced breast cancer?
Do we see a more pronounced absolute benefit in HER2-positive 
advanced breast cancer when everolimus is added to standard therapy 
in less heavily pretreated patients (BOLeRO-1) compared with the 
outcome observed in the BOLeRO-3 trial?
will we see improved outcome compared with everolimus-based 
therapy using second-generation mTOR inhibitors?
Abbreviations: BOLeRO, Breast cancer trials of OraL eveROlimus; HeR2, human 
epidermal growth factor receptor 2; Pi3K-AKT-mTOR, phosphatidylinositol-3-
kinase/protein kinase B/mammalian target of rapamycin.





breast cancer, many targeted drugs (including PI3K-AKT-
mTOR, cyclin-dependent-kinase, histone deacetylase, and 
Src inhibitors) in combination with endocrine therapy are 
under  development. The mTORC1 inhibitor everolimus 
is the first targeted therapy approved in HER2-negative, 
ER-positive advanced breast cancer resistant to nonsteroidal 
aromatase inhibitors based on the results of the BOLERO-2 
study. The magnitude of benefit has never been seen in this 
breast cancer subtype since the introduction of tamoxifen. 
The median progression-free survival has more than doubled 
when everolimus is added to exemestane compared with 
exemestane alone.17 Ongoing research is evaluating if more 
potent inhibition of the PI3K-AKT-mTOR pathway will 
lead to improved outcomes. The BOLERO-3 trial evaluat-
ing everolimus in heavily pretreated patients presenting 
HER2-positive advanced breast cancer also met its primary 
endpoint. Median progression-free survival is significantly 
improved when everolimus is added to trastuzumab and 
vinorelbine compared with placebo, trastuzumab, and 
vinorelbine. However, the benefit was only observed in 
HER2-positive, ER-negative tumors. This and other trials in 
the neoadjuvant and metastatic setting clearly indicate that 
new approaches are needed for HER2-positive, ER-positive 
breast cancer. The addition of an endocrine therapy to a drug 
combination targeting the PI3K-AKT-mTOR pathway and 
the HER2 receptor should be evaluated. The role of mTOR 
inhibitors in triple-negative breast cancer also warrants 
further evaluation.
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